Abstract | AIM: PATIENTS AND METHODS: The subjects included in the study were 169 patients with stage III colorectal cancer who underwent curative resection and received postoperative adjuvant chemotherapy between June 2007 and October 2014. Fifty-three patients were included in the OX group, while 116 patients were included in PO group. RESULTS: No significant difference was observed in treatment completion rates. No significant difference in either the overall or relapse-free survival rates was observed between the two groups. CONCLUSION:
|
Authors | Masayoshi Nakanishi, Yoshiaki Kuriu, Yasutoshi Murayama, Tomohiro Arita, Toshiyuki Kosuga, Ryo Morimura, Hirotaka Konishi, Syuhei Komatsu, Atsushi Shiozaki, Hisashi Ikoma, Daisuke Ichikawa, Hitoshi Fujiwara, Kazuma Okamoto, Eigo Otsuji |
Journal | Anticancer research
(Anticancer Res)
Vol. 36
Issue 4
Pg. 1851-4
(Apr 2016)
ISSN: 1791-7530 [Electronic] Greece |
PMID | 27069169
(Publication Type: Controlled Clinical Trial, Journal Article)
|
Copyright | Copyright© 2016 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved. |
Chemical References |
- Organoplatinum Compounds
- Oxaliplatin
- Capecitabine
|
Topics |
- Aged
- Antineoplastic Combined Chemotherapy Protocols
(adverse effects, therapeutic use)
- Capecitabine
(adverse effects, therapeutic use)
- Chemotherapy, Adjuvant
(adverse effects)
- Colorectal Neoplasms
(drug therapy, surgery)
- Female
- Humans
- Male
- Middle Aged
- Organoplatinum Compounds
(adverse effects, therapeutic use)
- Oxaliplatin
|